What it's for (Indications)
- Fusidic acid topical is indicated for the treatment of primary and secondary bacterial skin infections caused by susceptible strains of Staphylococcus aureus, Streptococcus species, and Corynebacterium minutissimum.
- These often include impetigo, folliculitis, furunculosis, erysipelas, and infected eczematous dermatitis.
- Oral isotretinoin is indicated for the treatment of severe recalcitrant nodular acne that is unresponsive to conventional therapy, including systemic antibiotics and topical treatments.
- It may also be used for other severe forms of acne that result in scarring, such as conglobate acne or acne fulminans.
- The combined use of topical fusidic acid and oral isotretinoin is typically employed in cases where severe acne is complicated by bacterial infection, aiming to address both the underlying acne pathophysiology and the superimposed bacterial component, ensuring a comprehensive approach to managing severe inflammatory acne.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | *Fusidic Acid Topical:* Typically applied sparingly to the affected skin areas two to three times daily, usually for a duration not exceeding two weeks, to minimize the risk of bacterial resistance development and potential for local irritation. The exact duration and frequency of application may vary based on the severity and extent of the infection, the patient's response to treatment, and local clinical guidelines. Adherence to the prescribed regimen is crucial for efficacy and to prevent antibiotic resistance. *Isotretinoin Oral:* The initial recommended dosage for oral isotretinoin is typically 0.5 to 1.0 mg/kg/day, administered in two divided doses with food, for a treatment course generally lasting 15 to 20 weeks. In severe cases or for patients with significant truncal acne, the dosage may be adjusted up to 2.0 mg/kg/day, but careful monitoring for dose-related side effects, particularly mucocutaneous and systemic effects, is paramount. The cumulative dose is often considered critical for achieving long-term remission, commonly ranging from 120 to 150 mg/kg per course. Close medical supervision, including regular follow-up appointments and laboratory tests, and strict adherence to specific monitoring protocols are essential throughout the entire treatment period. |
Safety & Warnings
Common Side Effects
- *Fusidic Acid Topical:* Common local reactions include mild irritation, burning, stinging, itching, rash, contact dermatitis, and dry skin at the application site.
- These reactions are generally transient and mild.
- Hypersensitivity reactions, though rare, can occur and may manifest as more severe localized swelling, generalized erythema, or urticaria, necessitating discontinuation of the medication.
- Prolonged or extensive use may potentially lead to the development of bacterial resistance, particularly among Staphylococcus species, diminishing the drug's effectiveness.
- *Isotretinoin Oral:* Systemic side effects are numerous and can range from common to severe.
- Very common effects (affecting >10% of patients) include severe cheilitis (dry, cracked lips, affecting >90%), xerosis (dry skin, >80%), dry mucous membranes, conjunctivitis (up to 40%), epistaxis, and musculoskeletal pain.
- Other common effects (1-10%) include headache, hair thinning (reversible), photosensitivity, elevated liver enzymes, and elevated triglycerides.
- Serious but less common side effects include pseudotumor cerebri, pancreatitis, mood alterations (e.
- g.
- , depression, suicidal ideation), severe skin reactions (e.
- g.
- , Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis), and ophthalmological issues like night vision impairment (potentially irreversible) and cataracts.
- Patients must be counselled on the extensive range of potential side effects.
Serious Warnings
- Black Box Warning: **Oral Isotretinoin Component: SEVERE TERATOGENICITY.** Isotretinoin is a potent human teratogen and can cause severe, life-threatening birth defects. **Any exposure during pregnancy, even for short periods, carries an extremely high risk of severe congenital malformations affecting the craniofacial, cardiac, central nervous system, and thymic regions.** Females of reproductive potential must not be pregnant and must use two reliable forms of contraception (a primary and a secondary method) simultaneously, for at least one month prior to initiating isotretinoin therapy, throughout the entire duration of therapy, and for one month after discontinuing therapy. Monthly pregnancy testing is mandatory prior to receiving each prescription refill to ensure non-pregnancy. This drug is available only through a highly restricted distribution program called iPLEDGE, designed to prevent any fetal exposure. All prescribers, dispensing pharmacies, and patients must be registered with and comply with all stringent requirements of the iPLEDGE program before isotretinoin can be prescribed or dispensed. Male patients must not donate blood during treatment and for at least one month after discontinuation of isotretinoin to prevent potential exposure to pregnant recipients through transfused blood. *Note: Topical fusidic acid does not carry a Black Box Warning.*
- *General for Combined Therapy:* Concurrent use of topical fusidic acid and oral isotretinoin should be carefully monitored to avoid potential drug interactions, additive systemic absorption risks, and overlapping side effects that could complicate patient management.
- *Fusidic Acid Topical:* Prolonged or widespread use of fusidic acid should be avoided to prevent the development of antimicrobial resistance, particularly with methicillin-resistant Staphylococcus aureus (MRSA) strains.
- Hypersensitivity reactions can occur, requiring immediate discontinuation of the drug.
- Patients should be advised to avoid contact with eyes, and if accidental contact occurs, to rinse thoroughly with water.
- It should not be used for bacterial infections caused by non-susceptible organisms.
- *Isotretinoin Oral:* **Teratogenicity:** EXTREME CAUTION is required due to the severe teratogenic risk (see Black Box Warning).
- **Psychiatric Effects:** There is a known risk of depression, psychosis, and rare reports of suicidal ideation/attempts.
- Patients should be monitored for any mood changes.
- **Hepatotoxicity:** Liver function tests must be monitored regularly (pre-treatment and periodically during treatment) as transaminase elevations can occur.
- **Hypertriglyceridemia:** Fasting lipid levels should be monitored (pre-treatment and periodically) as significant elevations in triglycerides can lead to pancreatitis.
- **Pseudotumor Cerebri (Benign Intracranial Hypertension):** Concurrent use of tetracyclines with isotretinoin is contraindicated due to an increased risk.
- Symptoms include headache, nausea, visual disturbances.
- **Inflammatory Bowel Disease:** Can exacerbate or induce inflammatory bowel disease.
- **Severe Skin Reactions:** Cases of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported; discontinue if severe skin reactions occur.
- **Impaired Night Vision:** Patients should be warned about potential sudden onset of night vision impairment, which can be permanent.
- **Blood Donation:** Patients must not donate blood during treatment and for at least one month after discontinuation to prevent exposure to pregnant recipients.
How it Works (Mechanism of Action)
*Fusidic Acid Topical:* Fusidic acid is an antimicrobial agent primarily effective against Gram-positive bacteria, particularly Staphylococcus species including Methicillin-Sensitive Staphylococcus aureus (MSSA) and some MRSA strains. Its mechanism of action involves inhibiting bacterial protein synthesis by interfering with the elongation factor G (EF-G) on the bacterial ribosome. Specifically, fusidic acid binds to EF-G, preventing its translocation from the A-site to the P-site on the ribosome, thereby blocking the synthesis of new proteins essential for bacterial growth and replication. Depending on the concentration achieved at the site of infection and the susceptibility of the bacterial organism, fusidic acid can exhibit both bacteriostatic (inhibiting growth) and bactericidal (killing bacteria) activity, providing effective treatment for susceptible bacterial skin infections.
*Isotretinoin Oral:* Isotretinoin is a synthetic retinoid, a derivative of vitamin A, that exerts its profound therapeutic effects in severe acne through multiple, interrelated mechanisms primarily targeting the pathogenesis of acne. It dramatically reduces the size and activity of sebaceous glands, leading to a significant and sustained decrease in sebum production, which is a key factor in the development and severity of acne. Furthermore, isotretinoin normalizes follicular keratinization, preventing the abnormal desquamation of keratinocytes and the formation of comedones and microcomedones, which are the primary precursor lesions of acne. It also possesses potent anti-inflammatory properties, reducing the inflammatory responses and lesion counts associated with severe acne. These combined actions lead to a comprehensive resolution of acne lesions, reduction in inflammation, and prevention of acne scarring.
Commercial Brands (Alternatives)
No other brands found for this formula.